The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.

T-Knife, a Germany-based developer of T-cell receptor therapeutics spun out of Max Delbrück Center for Molecular Medicine (MDC), has raised $110m in a series B round led by investment and financial services group Fidelity Management & Research Company. The round was filled out by sovereign wealth fund Qatar Investment Authority, Life Science Partners, Casdin Capital,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.